GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (XBUL:SNW) » Definitions » Return-on-Tangible-Asset

Sanofi (XBUL:SNW) Return-on-Tangible-Asset : 8.44% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Sanofi Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Sanofi's annualized Net Income for the quarter that ended in Jun. 2024 was лв9,037 Mil. Sanofi's average total tangible assets for the quarter that ended in Jun. 2024 was лв107,083 Mil. Therefore, Sanofi's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2024 was 8.44%.

The historical rank and industry rank for Sanofi's Return-on-Tangible-Asset or its related term are showing as below:

XBUL:SNW' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.69   Med: 10.04   Max: 24.02
Current: 8.04

During the past 13 years, Sanofi's highest Return-on-Tangible-Asset was 24.02%. The lowest was 5.69%. And the median was 10.04%.

XBUL:SNW's Return-on-Tangible-Asset is ranked better than
73.97% of 1045 companies
in the Drug Manufacturers industry
Industry Median: 2.05 vs XBUL:SNW: 8.04

Sanofi Return-on-Tangible-Asset Historical Data

The historical data trend for Sanofi's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Return-on-Tangible-Asset Chart

Sanofi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.62 25.11 11.80 15.31 10.15

Sanofi Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.30 19.88 13.01 7.58 8.44

Competitive Comparison of Sanofi's Return-on-Tangible-Asset

For the Drug Manufacturers - General subindustry, Sanofi's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Sanofi's Return-on-Tangible-Asset falls into.



Sanofi Return-on-Tangible-Asset Calculation

Sanofi's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=11006.054/( (109268.658+107494.498)/ 2 )
=11006.054/108381.578
=10.15 %

Sanofi's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=9037.144/( (107494.498+106671.304)/ 2 )
=9037.144/107082.901
=8.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Jun. 2024) net income data.


Sanofi  (XBUL:SNW) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Sanofi Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Sanofi's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanofi Business Description

Address
46, avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sanofi Headlines

No Headlines